{"id":"W4291012346","doi":"10.1016/j.ejca.2022.06.041","title":"Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sandoz; Merck Sharp and Dohme; EMD Serono; Genentech; Qbiotics; Sun Pharma; Astellas Pharma; Eisai; Daiichi-Sankyo; BeiGene; Regeneron Pharmaceuticals; Mylan; AstraZeneca; Amarin Corporation; Ono Pharmaceutical; Eli Lilly and Company; National Comprehensive Cancer Network; Les Laboratories Pierre Fabre; Array BioPharma; AbbVie; Daiichi Sankyo Europe; Bayer; Gilead Sciences; Sanofi; Celgene; Novartis; Merck; GlaxoSmithKline; American Society of Clinical Oncology; Bristol-Myers Squibb; Amgen; Hexal AG; Incyte; Pfizer; Gilead UK and Ireland Corporate Contributions; Castle Biosciences; Roche; Astellas Pharma US","keywords":"Medicine; Ipilimumab; Nivolumab; Melanoma; Cancer; Internal medicine; Hazard ratio; Oncology; Stage (stratigraphy); Adjuvant; Immunotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009964657,0.0001978801,0.0006051828,0.0002487317,0.00008171949,0.00002306997,0.000228926,0.00001474628,0.002427037],"category_scores_gemma":[0.00002386446,0.0001475744,0.0001935639,0.0002150435,0.00006992125,0.0001263372,0.00008527513,0.0003663011,0.000002437652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005627233,"about_ca_system_score_gemma":0.0003470104,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001075277,"about_ca_topic_score_gemma":0.00001768106,"domain_scores_codex":[0.9974603,0.0004226182,0.0008537561,0.0001968194,0.0008086202,0.0002578993],"domain_scores_gemma":[0.9986111,0.0000561629,0.0007551201,0.0002786288,0.0001960145,0.0001029619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.785193,0.001642053,0.1493143,0.00009717725,0.001318124,0.0002953662,0.002797327,0.0001452245,0.001624222,0.000008011484,0.001248147,0.05631703],"study_design_scores_gemma":[0.2973337,0.008689255,0.6768525,0.0002549986,0.0001865517,0.000006536161,0.001195283,0.00000704793,0.0002222409,4.118332e-7,0.01505987,0.0001916731],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954596,0.0007648071,0.00001497204,0.0003725218,0.001147895,0.0004481379,0.00006316566,0.000009077666,0.001719854],"genre_scores_gemma":[0.998228,0.0001515919,0.0002284531,0.0001350938,0.0001186655,0.000007104401,0.000008295817,0.00005594071,0.001066888],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5275381,"threshold_uncertainty_score":0.9984849,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02135862200431434,"score_gpt":0.3109600151685272,"score_spread":0.2896013931642129,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}